The Capital Markets team advised the joint lead book-running managers and underwriting syndicate in the completion of ImmunityBio’s (Nasdaq: IBRX) underwritten public offering of 33,333,334 shares of its common stock at a public offering price of $3.00 per share for gross proceeds of $100.0 million.
ImmunityBio is a vertically-integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases.
The Goodwin team was led by Bryan Quinn and included Justin Anslow, Harper Vincent, Daniel Karelitz and Maggie Wong.
For additional details on the offering, please read the press release.